ADDISON, Texas, April 15 /PRNewswire-FirstCall/ -- ULURU Inc. announced today that the company will present clinical evidence at the 2010 joint annual meeting of the Symposium on Advanced Wound Care and the Wound Healing Society (SAWC/WHS) in Orlando, Florida, April 17-20. SAWC/WHS is the premier wound care educational program within this clinical field and is the largest annual gathering of wound care clinicians in the United States. More than 2,000 physicians, podiatrists, nurses, therapists, and researchers are expected to attend the 2010 SAWC/WHS meeting. In addition to the presentation of the clinical evidence, the Company will also be providing educational guidance, showcasing advanced research on Altrazeal(TM) and products in the Altrazeal(TM) pipeline.
Altrazeal(TM) has shown a statistically significant decrease in pain in a randomized controlled clinical study. This effect is further demonstrated in a case study detailing pain management in patients with venous ulcers, to be presented by Catherine T. Milne, APRN, MSN, BC-ANP, CWOCN of Connecticut Clinical Nursing Associates, LC Bristol Hospital Wound, Ostomy, Lymphedema Center Bristol, Connecticut. Ms. Milne stated, “Wound pain is a tremendous burden for these patients. Having found a topical, cost effective method to reduce pain enhances patient compliance in wound care.”
A number of clinical posters by Greg Bohn, MD, FACS, Medical Director of the Trinity Center for Wound Care and Hyperbaric Medicine in Bettendorf, Iowa, explain multiple case studies where Altrazeal(TM) has been used successfully in difficult to heal wound types. Also, a poster describes how utilizing total contact casts with Altrazeal(TM) may shorten days to heal in neuropathic diabetic foot ulcers. Another poster will detail cases where techniques were developed to incorporate Altrazeal(TM) in the treatment of pressure ulcers, with pain and moisture management, in this difficult to treat class of wounds.
Renaat Van den Hooff, President and CEO of ULURU Inc., commented, “The clinical experience data that will be presented at the SAWC/WHS Symposium is compelling and highlights the clinical, pharma-economic and patient benefits that Altrazeal(TM) provides. This event comes only a week after a highly successful presentation of clinical evidence and Dr. Bohn’s presentation at the APWCA conference. These meetings allow more and more clinicians to discover the benefits that Altrazeal(TM) provides.”
A set of three advanced technology Altrazeal((TM)) posters have also been accepted for presentation at the prestigious Wound Healing Society Blue Ribbon Poster contest. These posters include a technique for moisture management of living skin equivalent constructs when combined with Altrazeal, details surrounding the effectiveness and importance of intimate contact between Altrazeal(TM) Silver and tissue and a poster on an innovative Nanoflex(TM) technology advancement utilizing ULURU’s gel formulation as a tunneling wound gel.
Information about SAWC/WHS and the annual spring meeting can be found at spring.sawc.net
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the benefits, effectiveness, biocompatibility, ease of application, success in wound healing, clinical outcomes, reimbursement and suitability of Altrazeal(TM), and the success of our clinical efforts. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed by us with the Securities and Exchange Commission.
CONTACT: Renaat Van den Hooff, President & CEO, or Terry K. Wallberg, Vice
President & CFO, +1-214-905-5145, both of ULURU Inc.
Web site: http://www.uluruinc.com/
